A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.
A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.
复制标题
DOI:
10.4049/jimmunol.0902255
复制
发表时间:
2010-01-01
期刊:
影响因子:
--
通讯作者:
Calderwood SK
中科院分区:
文献类型:
--
作者:
Gong J;Zhang Y;Durfee J;Weng D;Liu C;Koido S;Song B;Apostolopoulos V;Calderwood SK
In previous studies we have shown that HSP70-peptide complexes (HSP70.PC) derived from the fusion of dendritic cells (DC) to tumor cells (HSP70.PC-F) possess superior properties compared to HSP70.PC from tumor cells. HSP70.PC-F are more effective in stimulation of DC maturation and induction of CTL that are able to provide protection of mice against challenge with tumor cells. To develop an improved formulation of HSP70.PC-based tumor vaccine for patient use, we extracted HSP70.PC-F from DC fused to patient derived ovarian cancer or established human breast cancer cells and examined their properties as tumor vaccines. HSP70.PC-F induced T cells that express higher levels of IFN-γ and exhibit increased levels of killing of tumor cells compared to those induced by HSP70.PC derived from tumor cells. Enhanced immunogenicity of HSP70.PC-F was associated with improved composition of the vaccine including increased content of tumor antigens and their processed intermediates, and the detection of other HSPs such as HSP90 and HSP110. The present study has therefore provided an alternative approach to preparation of HSP-based vaccines using DC/tumor fusion technology and gentle and rapid isolation of HSP.PC.
登录
查看更多内容
影响因子:
3.1
作者:
Maki, Robert G.;Livingston, Philip O.;Brennan, Murray F.
通讯作者:
Brennan, Murray F.
影响因子:
4.4
作者:
Enomoto, Yutaka;Bharti, Ajit;Gong, Jianlin
通讯作者:
Gong, Jianlin
影响因子:
5.7
作者:
Mizukami, Shusaku;Kajiwara, Chiaki;Udono, Heiichiro
通讯作者:
Udono, Heiichiro
影响因子:
45.3
作者:
Belli, F;Testori, A;Parmiani, G
通讯作者:
Parmiani, G
影响因子:
5.7
作者:
Huang, CX;Yu, H;Cao, XT
通讯作者:
Cao, XT